Chemical Information | |
Antiviral agent ID | DrugRepV_5395 | |
Antiviral agent name | Amodiaquine | |
IUPAC Name | 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol | |
SMILES (canonical) | CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O | |
Molecular Formula | C20H22ClN3O | |
Molecular Weight (g/mol) | 355.87 | |
InChl | InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23) | |
Common Name | Amodiaquine | |
Synonyms | Amodiaquina | Amodiaquine | Amodiaquinum | |
Structural Information | |
|
|
Clinical Information | |
Category | Antiparasitic products, Insectisides and Repellents
| |
Primary Indication (Clinical trial phases) | Approved
| |
Biological Information | |
Primary Indication (Disease Category) | Infectious Disease
| |
Primary Indication (Disease) | Malaria
| |
Primary Indication (Drug target/Mode of Action) | Coagulation factor XIII B chain
| |
Secondary Indication | Lassa virus (LASV) NA Josiah | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | BSC-1
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Time of drug delivery) | Post infection
| |
Secondary Indication (Duration of drug delivery) | 24 hours
| |
Secondary Indication (Drug concentration) | 2.95 μM
| |
Secondary Indication (Cell based assay) | Luciferase assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | IC50 [ 50 % ] | |
Reference | Hulseberg CE, Feneant L, Szymanska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, Schmaljohn CS, Polyak SJ, White JM..Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses..J Virol. 2019 Apr 3;93(8). pii: e02185-18. doi: 10.1128/JVI.02185-18. Print 2019 Apr 15. PubMed Cent PMID:30700611
| |
Comment | Arbidol inhibits LASV fusion, which may partly involve blocking conformational changes in LASV GP.
| |